Daré Bioscience, Inc. (DARE): Price and Financial Metrics

Daré Bioscience, Inc. (DARE): $0.94

-0.01 (-1.03%)

POWR Rating

Component Grades













Add DARE to Watchlist
Sign Up

Industry: Biotech



in industry


  • DARE scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.42% of US stocks.
  • DARE's strongest trending metric is Value; it's been moving up over the last 179 days.
  • DARE's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

DARE Stock Summary

  • Of note is the ratio of DARE BIOSCIENCE INC's sales and general administrative expense to its total operating expenses; just 14.12% of US stocks have a lower such ratio.
  • For DARE, its debt to operating expenses ratio is greater than that reported by only 6.13% of US equities we're observing.
  • DARE's price/sales ratio is 7.85; that's higher than the P/S ratio of 85.81% of US stocks.
  • If you're looking for stocks that are quantitatively similar to DARE BIOSCIENCE INC, a group of peers worth examining would be PULM, PRQR, IMGN, TMBR, and OGEN.
  • DARE's SEC filings can be seen here. And to visit DARE BIOSCIENCE INC's official web site, go to www.darebioscience.com.

DARE Valuation Summary

  • DARE's price/earnings ratio is -3.2; this is 113.79% lower than that of the median Healthcare stock.
  • Over the past 105 months, DARE's EV/EBIT ratio has gone up 5.3.

Below are key valuation metrics over time for DARE.

Stock Date P/S P/B P/E EV/EBIT
DARE 2022-11-25 8.0 3.0 -3.2 -1.6
DARE 2022-11-23 7.9 3.0 -3.2 -1.6
DARE 2022-11-22 7.8 3.0 -3.2 -1.6
DARE 2022-11-21 8.0 3.0 -3.2 -1.6
DARE 2022-11-18 8.1 3.1 -3.3 -1.7
DARE 2022-11-17 8.1 3.1 -3.3 -1.7

DARE Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -185.66%.
  • Its 4 year net income to common stockholders growth rate is now at 58.65%.
  • Its 4 year net cashflow from operations growth rate is now at 50.49%.
Over the past 33 months, DARE's revenue has gone up $10,000,000.

The table below shows DARE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 10 -22.10766 -24.5468
2022-06-30 10 -29.38755 -30.19438
2022-03-31 0 -32.73049 -39.77113
2021-12-31 0 -28.76404 -38.69611
2021-09-30 0 -28.04189 -37.5953
2021-06-30 0 -34.71893 -32.51754

DARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DARE has a Quality Grade of D, ranking ahead of 8.05% of graded US stocks.
  • DARE's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • WINT, VCEL, and TEVA are the stocks whose asset turnover ratios are most correlated with DARE.

The table below shows DARE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 11.497
2021-03-31 0 NA 9.090
2020-12-31 0 NA 11.398
2020-09-30 0 NA 11.792
2020-06-30 0 NA 22.236
2020-03-31 0 NA 34.458

DARE Price Target

For more insight on analysts targets of DARE, see our DARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.40 Average Broker Recommendation 1.5 (Moderate Buy)

DARE Stock Price Chart Interactive Chart >

Price chart for DARE

DARE Price/Volume Stats

Current price $0.94 52-week high $2.51
Prev. close $0.95 52-week low $0.88
Day low $0.92 Volume 113,900
Day high $0.95 Avg. volume 1,093,808
50-day MA $0.96 Dividend yield N/A
200-day MA $1.19 Market Cap 79.75M

Daré Bioscience, Inc. (DARE) Company Bio

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.

DARE Latest News Stream

Event/Time News Detail
Loading, please wait...

DARE Latest Social Stream

Loading social stream, please wait...

View Full DARE Social Stream

Latest DARE News From Around the Web

Below are the latest news stories about DARE BIOSCIENCE INC that investors may wish to consider to help them evaluate DARE as an investment opportunity.

Maxim Group Sticks to Its Buy Rating for Daré Bioscience (DARE)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Daré Bioscience (DARE - Research Report) yesterday and set a price target of $4.00. The company's shares opened today at $0.96.According to TipRanks, McCarthy is an analyst with an average return of -38.1% and a 14.47% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.Daré Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $4.33, which is a 351.04% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.

Catie Powers on TipRanks | November 15, 2022

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | November 15, 2022

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the Point of Care in a Wide Range of Settings SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related

Yahoo | November 15, 2022

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with VVA Who Cannot, or Should Not, Take Supplemental Estrogen, Including Women with Hormone Receptor-Positive (HR+) Breast Cancer There are Currently No FDA-Approved Products Labeled for VVA Treatment for Patients with or at Risk of Recurrence of HR+ Breast Cancer SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE)

Yahoo | November 14, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Daré Bioscience (DARE - Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.92.According to TipRanks, Tsao is a 3-star analyst with an average return of 1.4% and a 38.44% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Daré Bioscience, RVL Pharmaceuticals, and Cabaletta Bio.Daré Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

Christine Brown on TipRanks | November 11, 2022

Read More 'DARE' Stories Here

DARE Price Returns

1-mo 0.00%
3-mo N/A
6-mo -28.79%
1-year -47.19%
3-year 15.34%
5-year -62.10%
YTD -53.00%
2021 49.25%
2020 63.41%
2019 15.49%
2018 -67.13%
2017 -69.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9105 seconds.